"description","label","id","instanceType","rationale","uuid:ID","name"
"The main design for the study","","StudyDesign_1","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","fff450f0-603a-4814-9da5-63a7bfc1bf72","Study Design 1"
